These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Patnaik MM; Tefferi A Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682 [TBL] [Abstract][Full Text] [Related]
5. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study. Fei F; Jariwala A; Pullarkat S; Loo E; Liu Y; Tizro P; Ali H; Otoukesh S; Amanam I; Artz A; Ally F; Telatar M; Nakamura R; Marcucci G; Afkhami M Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337700 [TBL] [Abstract][Full Text] [Related]
6. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms. Gerke MB; Christodoulou I; Karantanos T Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631 [TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. Patnaik MM; Lasho T Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673 [TBL] [Abstract][Full Text] [Related]
8. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview. Kuendgen A; Kasprzak A; Germing U Front Oncol; 2021; 11():778741. PubMed ID: 34869027 [TBL] [Abstract][Full Text] [Related]
9. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Patnaik MM; Tefferi A Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970 [TBL] [Abstract][Full Text] [Related]
10. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Szuber N; Orazi A; Tefferi A Am J Hematol; 2024 Jul; 99(7):1360-1387. PubMed ID: 38644693 [TBL] [Abstract][Full Text] [Related]
11. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959 [TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Kanagal-Shamanna R; Orazi A; Hasserjian RP; Arber DA; Reichard K; Hsi ED; Bagg A; Rogers HJ; Geyer J; Darbaniyan F; Do KA; Devins KM; Pozdnyakova O; George TI; Cin PD; Greipp PT; Routbort MJ; Patel K; Garcia-Manero G; Verstovsek S; Medeiros LJ; Wang SA; Bueso-Ramos C Mod Pathol; 2022 Apr; 35(4):470-479. PubMed ID: 34775472 [TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management". Patnaik MM; Tefferi A Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785 [TBL] [Abstract][Full Text] [Related]
14. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". Patnaik MM; Tefferi A Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061 [TBL] [Abstract][Full Text] [Related]
15. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis. Wan Z; Han B Front Oncol; 2020; 10():579221. PubMed ID: 33117717 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. Liu YC; Illar GM; Bailey NG J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616 [TBL] [Abstract][Full Text] [Related]
17. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes. Tiu RV; Sekeres MA Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705 [TBL] [Abstract][Full Text] [Related]
18. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Clara JA; Sallman DA; Padron E Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503 [TBL] [Abstract][Full Text] [Related]